Amgen is lagging behind rivals like Novo Nordisk and Eli Lilly with its new-generation therapy for obesity, but is sufficiently encouraged by early-stage clinical data to kick off a phase 2
Amgen and Sanofi have said they may make cash-only offers for Horizon Therapeutics, which confirmed it was in talks with potential buyers last week, but Johnson & Johnson has ruled itse
Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move a